Clinical trials: Monoclonal Antibody
Hematologic Neoplasms
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
The primary objective of this study is to characterize the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) of relatlimab administered alone or in combination with nivolumab to subjects with…
- Trial name
- NCT02061761
- Testing
- BMS-986016, BMS-936558
- Where
- 10 sites in United States, Canada
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Ankylosing Spondylitis
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
The purpose of this study is to evaluate the efficacy of intravenously (administration of a fluid into the vein) administered golimumab 2 milligram per kilogram (mg/kg) in participants with active ankylosing spondylitis (chronic…
- Trial name
- NCT02186873
- Testing
- Golimumab
- Where
- 45 sites in United States, Australia and 7 more
- Volunteers
- 208 people
- Sponsor
- Janssen Research & Development, LLC
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
RATIONALE: Pemetrexed disodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Studying samples of cerebrospinal fluid and blood from patients with cancer in the laboratory may help…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00424242
- Testing
- Pemetrexed
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
High-risk Smoldering Multiple Myeloma
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of siltuximab compared with placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial) in patients…
- Trial name
- NCT01484275
- Testing
- Siltuximab
- Where
- 40 sites in United States, Australia and 9 more
- Volunteers
- 85 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
Phase 2 AMG 714 in Rheumatoid Arthritis
Twelve week treatment of AMG 714 in RA patients who failed at least one DMARD, followed by a 3 month observational period.
- Trial name
- NCT00433875
- Testing
- AMG 714
- Volunteers
- 180 people
- Sponsor
- Amgen
Lymphoma
Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma
Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have recurrent non-Hodgkin's lymphoma.
- Trial name
- NCT00004101
- Testing
- apolizumab
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Ankylosing Spondylitis
A Clinical Study of JS005 in Patients With Ankylosing Spondylitis
This is a multicentre, randomized, double-blind, parallel, placebo-controlled Phase II clinical study of 261 adults with active ankylosing spondylitis to evaluate the efficacy and safety of JS005 in the treatment of active…
- Trial name
- NCT06250062
- Testing
- Recombinant humanized IL-17A Monoclonal Antibody（JS005）
- Where
- 38 sites in China
- Volunteers
- 265 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Treatment Efficacy
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer
A number of anti-PD-1/L1 monoclonal antibodies have been approved for the treatment of various advanced tumors in the world, and many studies on anti-PD-1 /L1 monoclonal antibodies for breast cancer are also being carried out.
- Trial name
- CHANGEABLE (NCT04508803)
- Testing
- HX008，Niraparib, HX008，Niraparib，Trastuzumab, HX008，Niraparib，Pyrrolitinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Fudan University
Lymphoma, Non-Hodgkin, Disease, Hodgkin
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
Phase I study to define the safety profile and pharmacokinetic parameters of SGN-35 in patients with relapsed/refractory CD30-positive hematologic malignancies.
- Conditions
- Lymphoma, Non-Hodgkin, Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic
- Trial name
- NCT00430846
- Testing
- SGN-35
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Seagen Inc.
Colon Cancer, Rectum Cancer
Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas
This study evaluates the safety and performance of SGM-101, a Carcinoembryonic Antigen (CEA)-specific chimeric antibody conjugated with a NIR emitting fluorochrome, for the visualization of CEA-expressing cancers during surgery.
- Conditions
- Colon Cancer, Rectum Cancer, Pancreas Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT02973672
- Testing
- SGM-101
- Where
- 3 sites in Netherlands
- Volunteers
- 75 people
- Sponsor
- Surgimab
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCL
The purpose of this study is to determine safety and tolerability of combination therapy of SGN-40 with gemcitabine and rituximab for the treatment of lymphoma.
- Trial name
- NCT00655837
- Testing
- SGN-40, rituximab, gemcitabine
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- Seagen Inc.
Diffuse Large B-cell Lymphoma (DLBCL)
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase I/II, open-label, multicenter, prospective study.
- Trial name
- NCT02957019
- Testing
- L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Philogen S.p.A.
Cutaneous T-Cell Lymphoma
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
The purpose of this trial is to determine the effect of HuMax-CD4 as a treatment for early stage cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT00071071
- Testing
- HuMax-CD4
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Genmab
Deep Vein Thrombosis
Clinical Trial to Evaluate the Accuracy of [99mTc] ThromboView in the Detection of Deep Vein Thrombosis
The assessment of patients with suspected deep vein thrombosis (DVT) is a common clinical scenario that, despite major advances in diagnostic testing, continues to be challenging.
- Trial name
- NCT00123734
- Testing
- ThromboView
- Where
- 12 sites in United States, Canada
- Volunteers
- 94 people
- Sponsor
- Agen Biomedical
Nasopharyngeal Carcinoma
Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of a combination regimen of Anti-PD1 monoclonal antibody, nimotuzumab, and capecitabin in treating recurrent or metastatic nasopharyngeal carcinoma patients who have…
- Trial name
- NCT06259721
- Testing
- Anti-PD1 antibody, nimotuzumab and capecitabine
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Systemic Juvenile Idiopathic Arthritis, Periodic Fever Syndrome
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection
This study is Safety, Tolerability and Pharmacokinetic of Recombinant anti-IL-1β Humanized Monoclonal Antibody injection in Healthy Subjects.
- Trial name
- NCT05027373
- Testing
- SSGJ-613
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Relapsed/Refractory Multiple Myeloma
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.
- Trial name
- NCT04309981
- Testing
- Adult differentiated autologous T-cells with anti-BCMA specificity
- Where
- 7 sites in Spain
- Volunteers
- 73 people
- Sponsor
- Sara V. Latorre
Multiple Sclerosis
Safety Study of GNbAC1 in Multiple Sclerosis Patients
The purpose of this study is to assess the safety and tolerability of single ascending doses, as well as of repeated administrations of GNbAC1 in MS patients.
- Trial name
- NCT01639300
- Testing
- GNbAC1
- Where
- 2 sites in Switzerland
- Volunteers
- 10 people
- Sponsor
- GeNeuro Innovation SAS
Colo-rectal Cancer, PD-1 Inhibitor
Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer
The investigators propose to conduct a single-center, single-arm, Phase I clinical study to explore the safety and feasibility of Akkermansia probiotics combined with anti-PD-1 monoclonal antibody in patients with MSS/pMMR…
- Conditions
- Colo-rectal Cancer, PD-1 Inhibitor, Akkermansia Muciniphila
- Trial name
- NCT06865521
- Testing
- Akkermansia Probiotics
- Where
- 2 sites in China
- Volunteers
- 22 people
- Sponsor
- West China Hospital
Migraine
MicroRNA Profile and Erenumab Treatment
Erenumab, a monoclonal antibody acting on the calcitonin gene-related peptide (CGRP) receptor, is an effective and safe migraine-specific preventive drug.
- Trial name
- NCT04659226
- Testing
- Blood sampling for microRNA testing
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- University of L'Aquila
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.